U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H31O2.Na
Molecular Weight 350.4701
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 6
Charge 0

SHOW SMILES / InChI
Structure of DOCONEXENT SODIUM

SMILES

[Na+].CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC([O-])=O

InChI

InChIKey=SNNDEWVSGZRIFE-FPYKSTABSA-M
InChI=1S/C22H32O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);/q;+1/p-1/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H31O2
Molecular Weight 327.4803
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 6
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.hsph.harvard.edu/nutritionsource/omega-3-fats/ | https://www.ncbi.nlm.nih.gov/pubmed/24352849 | https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm

Doconexent (Docosahexaenoic acid, DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. DHA is widely used as a food supplement, and is beleived to support healthy brain development in young childred, prevent cardiovascular disease and cognitive decline during Alzheimer's disease. Most of these claims, however, were not supported by clinical trials. DHA spray is used as a tanner.

CNS Activity

Originator

Approval Year

2007
205
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
Modulator
828
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Unknown

Approved Use

Unknown
Preventing
Approved
8429
Unknown

Approved Use

Unknown
Primary
Phase III
656
Unknown

Approved Use

Unknown
Palliative
Phase III
656
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Discovery of novel brain lipoxygenase products formed from docosahexaenoic acid (22:6w3).
1988
Nutrition and cognitive function.
1997 Apr
Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood cells.
1997 Aug
Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule.
1999 Apr
Maternal plasma homocysteine, placenta status and docosahexaenoic acid concentration in erythrocyte phospholipids of the newborn.
1999 Mar
Phytanic acid and docosahexaenoic acid increase the metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells.
2001 Oct 31
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
2003 Mar 28
Omega-3 status and cerebrospinal fluid corticotrophin releasing hormone in perpetrators of domestic violence.
2004 Dec 1
Effects of hyperglycemia and hypercapnia on lipid metabolism during complete brain ischemia.
2004 Dec 24
Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat.
2004 May
Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins-Mediator lipidomic analysis.
2005 Dec
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120.
2005 Jan
Differential modulation of the glutamate transporters GLT1, GLAST and EAAC1 by docosahexaenoic acid.
2005 Mar 10
TRPA1 is a polyunsaturated fatty acid sensor in mammals.
2012
New therapy using omega-3-Acid ethyl esters for decubitus ulcers and stasis dermatitis: a case report.
2014 Dec
Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.
2014 Jul
Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
2014 Nov
Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs.
2016 Jun
Kinetics of docosahexaenoic acid ethyl ester accumulation in dog plasma and brain.
2016 Oct
Highly Cross-Linked Epoxy Nanofiltration Membranes for the Separation of Organic Chemicals and Fish Oil Ethyl Esters.
2016 Sep 14
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
2017 Mar
[Separation of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester by simulated moving bed chromatography].
2018 Sep 8
Patents

Patents

JP1048898A
9
JP1050890A
4
JP1066118A
9
JP1066119A
9
JP1080250A
9
JP2000014392A
12
JP2000032954A
9
JP2000044470A
9
JP2000060439A
4
JP2000060587A
5
JP2000086425A
9
JP2000095683A
9
JP2000128805A
9
JP2000159667A
4
JP2000159682A
4
JP2000159792A
10
JP2000175630A
4
JP2000191525A
9
JP2000212588A
9
JP2000217538A
6
JP2000217582A
9
JP2000239168A
4
JP2000270885A
12
JP2000281572A
9
JP2000290178A
12
JP2000325040A
4
JP2000327570A
9
JP2000342291A
4
JP2001031566A
7
JP2001054396A
10
JP2001072993A
9
JP2001089380A
9
JP2001128642A
6
JP2001164286A
4
JP2001169780A
4
JP2001192328A
9
JP2001199892A
4
JP2001240558A
9
JP2001275656A
4
JP2001286234A
9
JP2001288079A
9
JP2001335794A
4
JP2002058435A
4
JP2002069475A
4
JP2002180082A
4
JP2002345452A
10
JP2002363131A
9
JP2002532687A
6
JP2002536294A
4
JP2003009818A
4
JP2003063942A
9
JP2004307428A
4
JP4761771B2
4
JP4828062B2
6
JPH00222228A
4
JPH02188574A
7
JPH0222228A
4
JPH07233058A
4
JPH0912456A
4
JPS60169418A
4
JPS62258362A
4

Sample Use Guides

In Vivo Use Guide
Doconexent is administered with food or as an oral supplement, or topically with food.
Route of Administration: Other
In Vitro Use Guide
DHA reduces calcium uptake in rat cardiac myocytes exposed to oubain (0.1 mM) after incubation for 4 days with 5 uM DHA added to medium. Calcium uptake was measured after addition of tracer 45Ca2+ to the 1.0 mM calcium in the bathing medium.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:32:27 UTC 2023
Edited
by admin
on Fri Dec 15 18:32:27 UTC 2023
Record UNII
295P7EPT4C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOCONEXENT SODIUM
Common Name English
4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, SODIUM SALT (1:1), (4Z,7Z,10Z,13Z,16Z,19Z)-
Common Name English
(ALL-Z)-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, SODIUM SALT
Common Name English
SODIUM (ALL-Z)-4,7,10,13,16,19-DOCOSAHEXAENOATE
Common Name English
Code System Code Type Description
CAS
81926-93-4
Created by admin on Fri Dec 15 18:32:27 UTC 2023 , Edited by admin on Fri Dec 15 18:32:27 UTC 2023
PRIMARY
PUBCHEM
71587300
Created by admin on Fri Dec 15 18:32:27 UTC 2023 , Edited by admin on Fri Dec 15 18:32:27 UTC 2023
PRIMARY
DRUG BANK
DBSALT002309
Created by admin on Fri Dec 15 18:32:27 UTC 2023 , Edited by admin on Fri Dec 15 18:32:27 UTC 2023
PRIMARY
FDA UNII
295P7EPT4C
Created by admin on Fri Dec 15 18:32:27 UTC 2023 , Edited by admin on Fri Dec 15 18:32:27 UTC 2023
PRIMARY
Related Record Type Details
Structure of DOCONEXENT
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of DOCONEXENT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966